Aging
Navigate
Submit an Article
Research Paper|Volume 12, Issue 15|pp 15392—15413

PDIA3 correlates with clinical malignant features and immune signature in human gliomas

Hao Zhang1,7, Yulai Zhou2,3,7, Quan Cheng1,3,4, Ziyu Dai1, Zeyu Wang1, Fangkun Liu1, Fan Fan1, Biqi Cui5, Hui Cao6
  • 1Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
  • 2Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
  • 3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
  • 4Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, China
  • 5Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
  • 6Department of Psychiatry, The Second People’s Hospital of Hunan Province, The Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
  • 7Equal contribution
Received: February 13, 2020Accepted: June 13, 2020Published: July 19, 2020
https://doi.org/10.18632/aging.103601

Copyright © 2020 Hao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Since therapeutic strategies are limited in gliomas, new molecules or biomarkers are essential for diagnosis and therapy. Here, we investigated expression of protein disulfide isomerase family A member 3 (PDIA3) in gliomas to evaluate its potential as a promising immune target or biomarker. Transcriptome level, genomic profiles and its association with clinical practice from TCGA and CGGA databases were analyzed. All statistical analyses were performed using R project. In gliomas with high PDIA3 expression, somatic mutations showed the correlation with loss of PTEN and amplification of EGFR; meanwhile, in PDIA3 low gliomas, mutations in isocitrate dehydrogenase (IDH) took 80%. Moreover, PDIA3 was found to positively correlate with ESTIMATE scores and diverse infiltrating immune and stromal cell types localizing in tumor microenvironment. PDIA3 was found to be highly correlated with macrophage and T cells based on single cell sequencing. Additionally, PDIA3 was also involved in suppression of anti-tumor immunity via multiple immune regulatory processes. Finally, PDIA3 was observed to correlate with other immune checkpoint inhibitors and associated with inflammation. Our findings identified the significance of PDIA3 in the process of gliomas and demonstrated the potential of PDIA3 as a molecular target in prognosis and immune related treatment of gliomas